Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients

BACKGROUND: Psoriasis is associated with metabolic, liver and cardiovascular comorbidity. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, has shown significant and sustained efficacy in the treatment of moderate to severe psoriasis. OBJECTIVES: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerdes, S., Pinter, A., Papavassilis, C., Reinhardt, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065121/
https://www.ncbi.nlm.nih.gov/pubmed/31599476
http://dx.doi.org/10.1111/jdv.16004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065121/
https://www.ncbi.nlm.nih.gov/pubmed/31599476
http://dx.doi.org/10.1111/jdv.16004

Ejemplares similares